ICU Medical (NASDAQ:ICUI) Stock Price Expected to Rise, Piper Sandler Analyst Says

Key Points

• Piper Sandler analysts raised ICU Medical's price target from $145.00 to $153.00, indicating a potential upside of 17.18%.
• ICU Medical reported earnings of $2.10 per share for the last quarter, exceeding estimates by $0.66, but experienced an 8.0% decline in year-over-year revenue.
• Insider transactions show significant purchases, with CEO Vivek Jain acquiring 21,929 shares at an average price of $112.84, boosting his holdings by 20.26%.

ICU Medical (NASDAQ:ICUI - Get Free Report) had its price objective hoisted by stock analysts at Piper Sandler from $145.00 to $153.00 in a research report issued on Wednesday, Marketbeat reports. The brokerage presently has an "overweight" rating on the medical instruments supplier's stock. Piper Sandler's price objective would suggest a potential upside of 17.18% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Raymond James Financial dropped their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating for the company in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $181.00.

ICU Medical Stock Performance

NASDAQ ICUI opened at $130.57 on Wednesday. ICU Medical has a 1-year low of $107.00 and a 1-year high of $196.26. The company has a market capitalization of $3.22 billion, a P/E ratio of -85.90 and a beta of 0.86. The business has a 50 day moving average price of $126.39 and a 200 day moving average price of $134.20. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17.

ICU Medical (NASDAQ:ICUI - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a positive return on equity of 7.24% and a negative net margin of 1.56%.The firm had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. During the same period last year, the business posted $1.56 EPS. ICU Medical's quarterly revenue was down 8.0% on a year-over-year basis. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Sell-side analysts expect that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Transactions at ICU Medical

In other ICU Medical news, Director David C. Greenberg bought 1,200 shares of the company's stock in a transaction dated Wednesday, August 27th. The shares were acquired at an average cost of $126.42 per share, with a total value of $151,704.00. Following the completion of the transaction, the director owned 7,960 shares in the company, valued at $1,006,303.20. The trade was a 17.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain bought 21,929 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were acquired at an average cost of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the transaction, the chief executive officer owned 130,149 shares of the company's stock, valued at approximately $14,686,013.16. The trade was a 20.26% increase in their position. The disclosure for this purchase can be found here. Insiders own 1.50% of the company's stock.

Institutional Trading of ICU Medical

Several hedge funds and other institutional investors have recently bought and sold shares of ICUI. Cullen Frost Bankers Inc. bought a new stake in ICU Medical in the second quarter valued at about $38,000. GAMMA Investing LLC increased its holdings in ICU Medical by 27.2% in the first quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 153 shares during the last quarter. Blue Trust Inc. increased its holdings in ICU Medical by 23.0% in the first quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock valued at $111,000 after buying an additional 150 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in ICU Medical by 11.6% in the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock valued at $128,000 after buying an additional 101 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in ICU Medical in the second quarter valued at about $177,000. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.